QS21
Phase 1Biologic
QS21 is one of 47 biologic programs targeting Kidney. It is currently in Phase 1.
2
Indications
15
Total Trials
1
Active Trials
46
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Adenocard
AstellasPreclinical
Lexiscan
AstellasPreclinical
Voltaren
NovartisPreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Tricor
JJagotec
Preclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
QS21
MMemorial Sloan Kettering Cancer Center
Phase 1
Ablavar
LLantheus Medical Imaging
Preclinical
Naltrexone/bupropion
Novo NordiskPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prostate Cancer4 trials
Breast Cancer3 trials
Melanoma2 trials
Colorectal Cancer1 trial
4 more indications
Chronic Myelogenous Leukemia1 trial
Peritoneal Cancer1 trial
Small Cell Lung Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for QS21. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details